Postdoctoral Associate – LbL Nanoparticle Systems for Delivery of Cytokine Proteins for Targeted Immuno-oncology:
This position in the Paula T. Hammond lab, at the Koch Institute of Integrative Cancer Research at MIT, will be filled by a biomaterials, chemical or biomedical engineer with strong materials science, biological and/or biomedical background and expertise in animal studies and histology. The project involves a collaboration with the Darrell J. Irvine lab, and will include joint interactions across labs. Background or interest in working with both in vivo and ex vivo tumor models such as organoids, and the use of high throughput methods to discover nanoparticle function and cell-material interactions is especially encouraged. This postdoctoral associate will examine the pharmacokinetics, biodistribution and modifications of the tumor microenvironment following delivery of combinations of different cytokines, with the potential to include additional therapeutics such as immunoregulators, to address advanced serous ovarian cancer. Broader sets of collaborations may also be possible within the Koch Institute Marble Center on Nanomedicine, including those involving combination therapy nanoparticle systems, theranostic systems, and the potential to explore other modes of immuno-oncology applications using nanomaterial systems.
Postdoctoral Associate – Cartilage-Penetrating Nanocarrier-Drug Conjugate for
Disease-Modifying Intervention in Post-Traumatic Osteoarthritis
This position in the Paula T. Hammond Lab at the MIT Koch Institute and Dept. of Chemical Engineering, will be filled by a biomedical engineer with significant experience with animal experiments and histology, and an interest in working on projects with a clinical goal. The project is a collaboration with the Alan Grodzinsky lab at MIT. The proposed work investigates dendritic based nanocarriers developed in our lab that are designed to penetrate cartilage to enable growth factors or other biologic drugs to get deep into the tissue to reach chondrocytes for extended periods for effective cartilage regeneration. The work includes conjugation of nanocarriers such as dendrimers, with high positive charge valency, to achieve desired penetration and pharmacokinetics in joints, and optimization of conjugation chemistry to achieve triggered release in the presence of inflammation, pH/hypoxia, or enzymes. The objective is to conduct translational research on this technology to evaluate and further develop the technology as a potential disease-modifying therapy for human posttraumatic osteoarthritis (PTOA). The project’s specific aims are to (1) explore and compare disease-modifying biologics with anabolic and anticatabolic mechanisms of action in osteoarthritis (OA), (2) perform dose-finding studies and toxicology of dendrimer-drug conjugates, and (3) evaluate improved delivery and efficacy of dendrimer-drug in a canine model (dog studies to be performed by a nearby contractor).